Comparison of acid inhibition attained by esomeprazole and vonoprazan with reference to CYP2C19 genotypes

Comparison of acid inhibition attained by esomeprazole and vonoprazan with reference to CYP2C19 genotypes - Comparison of esomeprazole and vonoprazan

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019890

Enrollment

Registered

2015-11-21

Start date

2015-02-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H. pylori infection and gastro-esophageal reflux desease

Interventions

There are four regimens as follows

(1) vonoprazan 20 mg twice daily for 7 days, (2) vonoprazan 20 mg once daily for 7 days, (3) esomeprazole 20 mg twice daily for 7 days, and (4) esomeprazole 20 mg once daily for 7 days. Subjects recei

interventions 1-24&quot

. &quot

Interventions 11-24&quot

are mentioned in &quot

other related information&quot

, because of lack of the space. A clinical research coordinator manages the dosing schedule of each subject. The washout period between the different regimens is at least 2 weeks. In each regimen, 24

regimen (1), washout (at least 2 weeks), regimen (2), washout (at least 2 weeks), regimen (3), washout (at least 2 weeks), and regimen (4) Interventions 2

regimen (1), washout (at least 2 weeks), regimen (2), washout (at least 2 weeks), regimen (4), washout (at least 2 weeks), and regimen (3) Interventions 3

regimen (1), washout (at least 2 weeks), regimen (3), washout (at least 2 weeks), regimen (2), washout (at least 2 weeks), and regimen (4) Interventions 4

regimen (1), washout (at least 2 weeks), regimen (3), washout (at least 2 weeks), regimen (4), washout (at least 2 weeks), and regimen (2) Interventions 5

regimen (1), washout (at least 2 weeks), regimen (4), washout (at least 2 weeks), regimen (2), washout (at least 2 weeks), and regimen (3) Interventions 6

regimen (1), washout (at least 2 weeks), regimen (4), washout (at least 2 weeks), regimen (3), washout (at least 2 weeks), and regimen (2) Interventions 7

regimen (2), washout (at least 2 weeks), regimen (1), washout (at least 2 weeks), regimen (3), washout (at least 2 weeks), and regimen

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy Japanese men and women

Exclusion criteria

Exclusion criteria: Exclusion criteria are any underlying disease, smoking habit, past or present H. pylori infection, and habitual use of any medicine.

Design outcomes

Primary

Measure	Time frame
The primary outcome is acid inhibition with the four regimens as assessed by 24-hour intragastric pH monitoring on Day7 in each regimen.	—

Secondary

Measure	Time frame
The secondary outcomes is serum gastrin level on Day 7 with each regimen as a surrogate marker of acid inhibition.	—

Countries

Japan

Contacts

Public ContactTakahisa Furuta

Hamamatsu University School of Medicine Center for Clinical Research

furuta@hama-med.ac.jp+81-53-435-2261

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026